B1 summary ( Arabic Translate )
B1 summary ( Arabic Translate )
B1 summary ( Arabic Translate )
As one of the most common types of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is highly invasive and lethal. This study aims to develop biomarkers and targets for the diagnosis and treatment of PDAC. Differentially expressed genes (DEGs) were screened via GEO2R, protein network was constructed through STRING and Cytoscape. Functional enrichment analysis was performed, followed by survival analysis and expression validation. A total of 115 DEGs were identified, including 108 upregulated and 7 downregulated genes. After enrichment, survival analysis, one potential gene, Cyclin B1 (CCNB1), was selected for further expression verification at the mRNA and protein level. Taker together, CCNB1 may act as a potential biomarker which provided new idea for elucidation of the pathogenesis of PDAC.
Introduction
More than 200,000 people die from pancreatic cancer each year, one of the highly malignant tumors of the digestive system, which makes pancreatic cancer the seventh leading cause of cancer death worldwide1. Pancreatic cancer has nearly the same number of deaths and cases, with the highest rates in Europe and North America2. Among all cancer types, pancreatic cancer has the lowest 5-year survival rate of 3%-15%, and is projected to be the second leading cause of cancer-related death in the United States by 20303,4. PDAC accounts for over 90 percent of pancreatic malignancies, and it is one of the most prevalent cancer type5,6. Compared with lung, breast, colorectal and gastric cancers, PDAC has a lower incidence but higher mortality. The clinical prognosis of PDAC is generally poor, with one-year and five-year survival ratio of only 24% and 9%, respectively7,8. Genetics, smoking, high-fat diet and chronic pancreatitis, etc. are closely related to the occurrence of PDAC9. At present, surgical resection remains the preferred options for the treatment of PDAC. However, due to the latent and occult nature of pancreatic cancer, most patients are diagnosed too late, and the tumor tissue has already invaded and formed distant metastasis, which reduced the effect of surgical treatment10. Furthermore, postoperative chemotherapy is unsatisfactory due to drug resistance11. Therefore, finding specific markers for early diagnosis and treatment is of great significance for improving the prognosis and survival ratio of PDAC patients.
B1 summary ( Arabic Translate )
As one of the most common types of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is highly invasive and lethal. This study aims to develop biomarkers and targets for the diagnosis and treatment of PDAC. Differentially expressed genes (DEGs) were screened via GEO2R, protein network was constructed through STRING and Cytoscape. Functional enrichment analysis was performed, followed by survival analysis and expression validation. A total of 115 DEGs were identified, including 108 upregulated and 7 downregulated genes. After enrichment, survival analysis, one potential gene, Cyclin B1 (CCNB1), was selected for further expression verification at the mRNA and protein level. Taker together, CCNB1 may act as a potential biomarker which provided new idea for elucidation of the pathogenesis of PDAC.
Introduction
More than 200,000 people die from pancreatic cancer each year, one of the highly malignant tumors of the digestive system, which makes pancreatic cancer the seventh leading cause of cancer death worldwide1. Pancreatic cancer has nearly the same number of deaths and cases, with the highest rates in Europe and North America2. Among all cancer types, pancreatic cancer has the lowest 5-year survival rate of 3%-15%, and is projected to be the second leading cause of cancer-related death in the United States by 20303,4. PDAC accounts for over 90 percent of pancreatic malignancies, and it is one of the most prevalent cancer type5,6. Compared with lung, breast, colorectal and gastric cancers, PDAC has a lower incidence but higher mortality. The clinical prognosis of PDAC is generally poor, with one-year and five-year survival ratio of only 24% and 9%, respectively7,8. Genetics, smoking, high-fat diet and chronic pancreatitis, etc. are closely related to the occurrence of PDAC9. At present, surgical resection remains the preferred options for the treatment of PDAC. However, due to the latent and occult nature of pancreatic cancer, most patients are diagnosed too late, and the tumor tissue has already invaded and formed distant metastasis, which reduced the effect of surgical treatment10. Furthermore, postoperative chemotherapy is unsatisfactory due to drug resistance11. Therefore, finding specific markers for early diagnosis and treatment is of great significance for improving the prognosis and survival ratio of PDAC patients.
B1 summary ( Arabic Translate )
As one of the most common types of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is highly invasive and lethal. This study aims to develop biomarkers and targets for the diagnosis and treatment of PDAC. Differentially expressed genes (DEGs) were screened via GEO2R, protein network was constructed through STRING and Cytoscape. Functional enrichment analysis was performed, followed by survival analysis and expression validation. A total of 115 DEGs were identified, including 108 upregulated and 7 downregulated genes. After enrichment, survival analysis, one potential gene, Cyclin B1 (CCNB1), was selected for further expression verification at the mRNA and protein level. Taker together, CCNB1 may act as a potential biomarker which provided new idea for elucidation of the pathogenesis of PDAC.
Introduction
More than 200,000 people die from pancreatic cancer each year, one of the highly malignant tumors of the digestive system, which makes pancreatic cancer the seventh leading cause of cancer death worldwide1. Pancreatic cancer has nearly the same number of deaths and cases, with the highest rates in Europe and North America2. Among all cancer types, pancreatic cancer has the lowest 5-year survival rate of 3%-15%, and is projected to be the second leading cause of cancer-related death in the United States by 20303,4. PDAC accounts for over 90 percent of pancreatic malignancies, and it is one of the most prevalent cancer type5,6. Compared with lung, breast, colorectal and gastric cancers, PDAC has a lower incidence but higher mortality. The clinical prognosis of PDAC is generally poor, with one-year and five-year survival ratio of only 24% and 9%, respectively7,8. Genetics, smoking, high-fat diet and chronic pancreatitis, etc. are closely related to the occurrence of PDAC9. At present, surgical resection remains the preferred options for the treatment of PDAC. However, due to the latent and occult nature of pancreatic cancer, most patients are diagnosed too late, and the tumor tissue has already invaded and formed distant metastasis, which reduced the effect of surgical treatment10. Furthermore, postoperative chemotherapy is unsatisfactory due to drug resistance11. Therefore, finding specific markers for early diagnosis and treatment is of great significance for improving the prognosis and survival ratio of PDAC patients.
B1 summary ( Arabic Translate )
As one of the most common types of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) is highly invasive and lethal. This study aims to develop biomarkers and targets for the diagnosis and treatment of PDAC. Differentially expressed genes (DEGs) were screened via GEO2R, protein network was constructed through STRING and Cytoscape. Functional enrichment analysis was performed, followed by survival analysis and expression validation. A total of 115 DEGs were identified, including 108 upregulated and 7 downregulated genes. After enrichment, survival analysis, one potential gene, Cyclin B1 (CCNB1), was selected for further expression verification at the mRNA and protein level. Taker together, CCNB1 may act as a potential biomarker which provided new idea for elucidation of the pathogenesis of PDAC.
Introduction
More than 200,000 people die from pancreatic cancer each year, one of the highly malignant tumors of the digestive system, which makes pancreatic cancer the seventh leading cause of cancer death worldwide1. Pancreatic cancer has nearly the same number of deaths and cases, with the highest rates in Europe and North America2. Among all cancer types, pancreatic cancer has the lowest 5-year survival rate of 3%-15%, and is projected to be the second leading cause of cancer-related death in the United States by 20303,4. PDAC accounts for over 90 percent of pancreatic malignancies, and it is one of the most prevalent cancer type5,6. Compared with lung, breast, colorectal and gastric cancers, PDAC has a lower incidence but higher mortality. The clinical prognosis of PDAC is generally poor, with one-year and five-year survival ratio of only 24% and 9%, respectively7,8. Genetics, smoking, high-fat diet and chronic pancreatitis, etc. are closely related to the occurrence of PDAC9. At present, surgical resection remains the preferred options for the treatment of PDAC. However, due to the latent and occult nature of pancreatic cancer, most patients are diagnosed too late, and the tumor tissue has already invaded and formed distant metastasis, which reduced the effect of surgical treatment10. Furthermore, postoperative chemotherapy is unsatisfactory due to drug resistance11. Therefore, finding specific markers for early diagnosis and treatment is of great significance for improving the prognosis and survival ratio of PDAC patients.
235,45 Mb
🍏 How to Download from germanvibes : https://youtu.be/bcTG7lYSeBQ
